Participated · Series A · Jun 2026

Straiker provides an agentic-native security platform with three integrated capabilities: comprehensive discovery of AI agents across enterprise environments, pre-deployment adversarial testing to surface vulnerabilities, and runtime protection that monitors activity and stops threats. The founding team includes veterans of Palo Alto Networks and AI/security research, and the company emphasizes a shared intelligence layer that uses production detections to strengthen testing and protections. Since launching in 2025, Straiker has become a partner to frontier AI labs and Fortune 500 enterprises and reports run-rate revenue growth of more than 15x in less than a year. Straiker operates STAR Labs, its dedicated AI threat research arm, which informs its defenses and provides early visibility into emerging attack techniques.

Led · Series B · May 2026

NUCLIDIUM focuses on copper isotopes for radiotheranostics, using copper-61 for imaging and copper-67 for therapeutic applications. Its lead programs are NU101 for metastatic castration-resistant prostate cancer and NU201 for metastatic breast cancer, both slated to begin therapeutic phase 1/2a trials this year. The company reports that diagnostic phase 1/2 trial data to date show strong momentum, according to CEO and co-founder Leila Jaafar. NUCLIDIUM operates sites in Basel and Munich and is currently in the clinical development phase. It plans to expand its international production and manufacturing network for diagnostics and therapy and to develop new target structures in preclinical work to address additional solid tumor types.

Participated · Series B · Nov 2025

AAVantgarde Bio is advancing best-in-class AAV gene therapies aimed at treating severe inherited retinal diseases (IRDs) that currently have no approved therapies. Its lead candidate, AAVB-039, is being evaluated in the CELESTE study to address Stargardt disease caused by ABCA4 mutations, alongside the >100-patient STELLA natural history study. A second program, AAVB-081, is in a Phase 1/2 LUCE trial for retinitis pigmentosa secondary to Usher syndrome type 1B arising from MYO7A mutations. Led by CEO Dr. Natalia Misciattelli, the company plans to use newly secured capital to achieve clinical proof-of-concept for both programs. The pipeline positions AAVantgarde to enter mid-stage development in two large, unmet IRD markets. Financially, the company has just closed a substantial $141 million Series B round to fund these milestones, underscoring strong investor confidence in its platform. No revenue or patient adoption metrics have yet been disclosed, consistent with its clinical-stage status.

Participated · Series B · Oct 2025

Caracol provides turnkey robotic manufacturing systems, branded Heron AM and Vipra AM, that integrate in-house hardware, advanced software and robotics to print large-scale parts in polymers and metals. The company has installed more than 100 robotic platforms worldwide and supports hundreds of customer projects, delivering outcomes such as 70 % cost savings for yacht builder Ferretti Group and 50 % lead-time reductions for composites specialist Duqueine. Headquartered in Milan with hubs in Austin and Dubai, Caracol employs over 100 people and maintains a footprint in 50-plus countries. Revenues have more than doubled year-over-year for the past five years, a trajectory that continued through the first half of 2025. Fresh capital will be used to fortify its leadership in Europe, the United States and the Middle East, expand into Asia-Pacific, and deepen its multi-process, multi-material platform with enhanced software, automation and AI-driven process control. The company also plans to accelerate its metal additive manufacturing offering for regulated industries while scaling its polymer solutions across transportation, construction and architecture. Recent strategic moves include expanding a Texas headquarters and acquiring the additive robotic IP of Germany’s Hans Weber Maschinenfabrik to bolster its European technology base.

Participated · Series B · Sep 2025

Founded in 2020 and headquartered in Schwyz, Switzerland, deskbird offers an all-in-one workplace management platform available via mobile app, web, Microsoft Teams, and Slack. The software lets employees book desks, meeting rooms, parking spots, and guest access and plan their weekly schedules, while providing employers analytics to right-size real estate, improve collaboration, and cut waste. deskbird is building AI-powered workplace intelligence that will deliver predictive space-usage insights and help create adaptive offices. The company already serves more than 10,000 offices and 250,000 users worldwide, with enterprise customers such as Samsung, Deloitte, Philips, and Airbus. Revenue figures were not disclosed, but the customer base and user metrics point to meaningful market traction. Fresh Series B capital will fund continued product innovation, deeper integrations, and geographic expansion across the UK, broader Europe, and additional international markets. The firm positions itself at the intersection of hybrid work enablement and real-estate efficiency, two sizable and growing themes.